ReviewThe Journal of general virology2013
Recent developments in human immunodeficiency virus-1 latency research.
Review in The Journal of general virology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 20 citations in OpenAlex.
- Review
- Article
- HIV-1 uses dynamic podosomes for entry into macrophages.Journal of virology · 2021Article
- Single-cell analysis of HIV-1 transcriptional activity reveals expression of proviruses in expanded clones during ART.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- Simplified Bryostatin Analogues Protect Cells from Chikungunya Virus-Induced Cell Death.Journal of natural products · 2016Article
- Temporal transcriptional response to latency reversing agents identifies specific factors regulating HIV-1 viral transcriptional switch.Retrovirology · 2015Article
- Studies on the regio- and diastereo-selective epoxidation of daphnanes and tiglianes.Tetrahedron letters · 2015Article
- Toward a biorelevant structure of protein kinase C bound modulators: design, synthesis, and evaluation of labeled bryostatin analogues for analysis with rotational echo double resonance NMR spectroscopy.Journal of the American Chemical Society · 2015Article
- Preparation, characterization, and safety evaluation of poly(lactide-co-glycolide) nanoparticles for protein delivery into macrophages.International journal of nanomedicine · 2015Article
- Improved protein kinase C affinity through final step diversification of a simplified salicylate-derived bryostatin analog scaffold.Organic letters · 2014Article
- Computer-guided design, synthesis, and protein kinase C affinity of a new salicylate-based class of bryostatin analogs.Organic letters · 2014Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Almost 30 years after its initial discovery, infection with the human immunodeficiency virus-1 (HIV-1) remains incurable and the virus persists due to reservoirs of latently infected CD4(+) memory T-cells and sanctuary sites within the infected individual where drug penetration is poor. Reactivating latent viruses has been a key strategy to completely eliminate the virus from the host, but many difficulties and unanswered questions remain. In this review, the latest developments in HIV-persistence and latency research are presented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.